IRRC CORPORATION

Press Releases IRRC Corporation

Equities

7325

JP3105230001

Delayed Japan Exchange Other stock markets 11:30:00 13/05/2024 am IST			5-day change	1st Jan Change
735 ^JPY	+1.38%		+2.37%	+13.78%

19/02	Tranche Update on IRRC Corporation's Equity Buyback Plan announced on August 18, 2023.	CI
16/02	IRRC Corporation's Equity Buyback announced on August 18, 2023, has closed with 200,000 shares, representing 2.39% for ¥140.90 million.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Henlius Biotech, Inc. - Results from Four Phase 1/2 Clinical Trials of Henlius Innovative Products Released at 2023 ESMO Asia	05/12	AQ
CStone Announces Publication of GEMSTONE-201 Study Results for Sugemalimab Monotherapy in the Treatment of Relapsed, Refractory Extranodal NK/T-Cell Lymphoma in Journal of Clinical Oncology	31/23/31	AQ
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan	21/22/21	AQ
CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022	06/22/06	AQ
IRRC : Pennsylvania Takes Next Step Toward Cap-and-Trade Amid Resistance	30/21/30	AQ
Worth Another Look: Regional Greenhouse Gas Initiative (RGGI)	14/21/14	AQ
IRRC : New Overtime Pay Regulation In Pennsylvania May Create Obligations For Employers Beyond Federal Requirements	25/20/25	AQ
Gilead Sciences : U.S. FDA Grants Priority Review for Kite's KTE-X19 Biologics License Application in Relapsed or Refractory Mantle Cell Lymphoma	11/20/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW